Oncostatin M is a growth factor for Ewing sarcoma.

[1]  S. Chevalier,et al.  Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling , 2012, Stem cells.

[2]  M. Jackson,et al.  c-MYC functions as a molecular switch to alter the response of human mammary epithelial cells to oncostatin M. , 2011, Cancer research.

[3]  C. Smith,et al.  Endothelium-derived GM-CSF influences expression of oncostatin M. , 2011, American journal of physiology. Cell physiology.

[4]  H. Hirai,et al.  Regulation of embryonic stem cell self-renewal and pluripotency by leukaemia inhibitory factor. , 2011, The Biochemical journal.

[5]  Ying Yue,et al.  Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3. , 2011, International journal of molecular medicine.

[6]  Jiayuh Lin,et al.  The Small Molecule, LLL12, Inhibits STAT3 Phosphorylation and Induces Apoptosis in Medulloblastoma and Glioblastoma Cells , 2011, PloS one.

[7]  M. Pennell,et al.  Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines , 2011, BMC Cancer.

[8]  J. Shin,et al.  Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer , 2011, Molecules and cells.

[9]  Jong-In Park,et al.  Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. , 2010, Cancer letters.

[10]  Nicolò Riggi,et al.  EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. , 2010, Genes & development.

[11]  Annalisa Astolfi,et al.  CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. , 2010, The Journal of clinical investigation.

[12]  A. Cleton-Jansen,et al.  Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2 , 2009, The Journal of pathology.

[13]  R. McLendon,et al.  Targeting Interleukin 6 Signaling Suppresses Glioma Stem Cell Survival and Tumor Growth , 2009, Stem cells.

[14]  V. Ferré,et al.  Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. , 2009, Bone.

[15]  E. Barillot,et al.  The Oncogenic EWS-FLI1 Protein Binds In Vivo GGAA Microsatellite Sequences with Potential Transcriptional Activation Function , 2009, PloS one.

[16]  F. Blanchard,et al.  The dual role of IL-6-type cytokines on bone remodeling and bone tumors. , 2009, Cytokine & growth factor reviews.

[17]  Jim Yang,et al.  Stat3 and c-Myc Genome-Wide Promoter Occupancy in Embryonic Stem Cells , 2008, PloS one.

[18]  B. Dréno,et al.  Relationship between responsiveness of cancer cells to Oncostatin M and/or IL‐6 and survival of stage III melanoma patients treated with tumour‐infiltrating lymphocytes , 2008, The Journal of pathology.

[19]  P. Hogendoorn,et al.  A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma , 2008, The Journal of pathology.

[20]  D. Heymann,et al.  Oncostatin M Induces Bone Loss and Sensitizes Rat Osteosarcoma to the Antitumor Effect of Midostaurin In vivo , 2008, Clinical Cancer Research.

[21]  N. D. Clarke,et al.  Integration of External Signaling Pathways with the Core Transcriptional Network in Embryonic Stem Cells , 2008, Cell.

[22]  G. I. Gallicano,et al.  Regulation of Sox2 by STAT3 initiates commitment to the neural precursor cell fate. , 2008, Stem cells and development.

[23]  S. Battaglia,et al.  Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53 , 2007, Oncogene.

[24]  O. Delattre,et al.  Mesenchymal stem cell features of Ewing tumors. , 2007, Cancer cell.

[25]  B. Dréno,et al.  Loss of oncostatin M receptor β in metastatic melanoma cells , 2007, Oncogene.

[26]  P. Picci.  Osteosarcoma (Osteogenic sarcoma) , 2007, Orphanet journal of rare diseases.

[27]  A. Yoshimura,et al.  Loss of SOCS3 Gene Expression Converts STAT3 Function from Anti-apoptotic to Pro-apoptotic* , 2006, Journal of Biological Chemistry.

[28]  H. Kovar,et al.  Ewing ’ s Sarcoma Family of Tumors : Current Management , 2006 .

[29]  D. Heymann,et al.  Osteosarcoma: current status of immunotherapy and future trends (Review). , 2006, Oncology reports.

[30]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[31]  A. Pession,et al.  The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. , 2005, Current cancer drug targets.

[32]  A. Papavassiliou,et al.  Growth Hormone Attenuates the Transcriptional Activity of Runx2 by Facilitating Its Physical Association With Stat3β , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  E. Benveniste,et al.  Oncostatin M: a pleiotropic cytokine in the central nervous system. , 2004, Cytokine & growth factor reviews.

[34]  Holm Zaehres,et al.  LIF/STAT3 Signaling Fails to Maintain Self‐Renewal of Human Embryonic Stem Cells , 2004, Stem cells.

[35]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[36]  C. Watson,et al.  A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland , 2003, Development.

[37]  O. Coqueret,et al.  Kaposi sarcoma-associated viral cyclin K overrides cell growth inhibition mediated by oncostatin M through STAT3 inhibition. , 2003, Blood.

[38]  Akihiro Umezawa,et al.  Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma , 2003, Oncogene.

[39]  T. Hirano,et al.  STAT3 Down-regulates the Expression of Cyclin D during Liver Development* , 2002, The Journal of Biological Chemistry.

[40]  J. Dewille,et al.  Oncostatin M Induces Growth Arrest of Mammary Epithelium via a CCAAT/enhancer-binding Protein δ-dependent Pathway1Supported in part by NIH Grant RR00136CA (to J. A. H.) and NIH Grants CA 57607 and P30CA16058 from the National Cancer Institute (to J. W. D.).1 , 2002 .

[41]  H. Baumann,et al.  Oncostatin M Regulates the Synthesis and Turnover of gp130, Leukemia Inhibitory Factor Receptor α, and Oncostatin M Receptor β by Distinct Mechanisms* , 2001, The Journal of Biological Chemistry.

[42]  O. Delattre,et al.  Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression , 2001, Oncogene.

[43]  T. Hara,et al.  Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. , 2000, The American journal of pathology.

[44]  A. Craft,et al.  Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  H. Baumann,et al.  Stimulation of Leukemia Inhibitory Factor Receptor Degradation by Extracellular Signal-regulated Kinase* , 2000, The Journal of Biological Chemistry.

[46]  Hong Li,et al.  Expression of leukemia-inhibitory factor as an autocrinal growth factor in human medulloblastomas , 1999, Journal of Cancer Research and Clinical Oncology.

[47]  U. Klingmüller,et al.  Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1 , 1999, Oncogene.

[48]  H J Mankin,et al.  Chondrosarcoma of bone: an assessment of outcome. , 1999, The Journal of bone and joint surgery. American volume.

[49]  A. Boutten,et al.  Oncostatin M production and regulation by human polymorphonuclear neutrophils. , 1999, Blood.

[50]  P. Roberson,et al.  Transcriptional Activation of the p21 WAF1,CIP1,SDI1 Gene by Interleukin-6 Type Cytokines , 1998, The Journal of Biological Chemistry.

[51]  J. Toguchida,et al.  p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. , 1993, British Journal of Cancer.

[52]  C. Denny,et al.  Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[53]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[54]  G. Todaro,et al.  Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[55]  D. Heymann,et al.  Direct anti-cancer effect of oncostatin M on chondrosarcoma , 2011 .

[56]  R. Arceci.  Fusion Gene–Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma , 2010 .

[57]  Y. Oda,et al.  A role for leukemia inhibitory factor in melanoma-induced bone metastasis , 2008, Clinical & Experimental Metastasis.

[58]  B. Dréno,et al.  Loss of oncostatin M receptor beta in metastatic melanoma cells. , 2007, Oncogene.